BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22983009)

  • 1. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation.
    Marchesi I; Fiorentino FP; Rizzolio F; Giordano A; Bagella L
    Cell Cycle; 2012 Oct; 11(20):3828-36. PubMed ID: 22983009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors.
    MacQuarrie KL; Yao Z; Fong AP; Diede SJ; Rudzinski ER; Hawkins DS; Tapscott SJ
    Mol Cell Biol; 2013 Feb; 33(4):773-84. PubMed ID: 23230269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.
    Marchesi I; Giordano A; Bagella L
    Cell Cycle; 2014; 13(4):516-27. PubMed ID: 24496329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
    Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
    Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding.
    Li S; Chen K; Zhang Y; Barnes SD; Jaichander P; Zheng Y; Hassan M; Malladi VS; Skapek SX; Xu L; Bassel-Duby R; Olson EN; Liu N
    Genes Dev; 2019 Jun; 33(11-12):626-640. PubMed ID: 30975722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
    Caretti G; Di Padova M; Micales B; Lyons GE; Sartorelli V
    Genes Dev; 2004 Nov; 18(21):2627-38. PubMed ID: 15520282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD.
    Knudsen ES; Pazzagli C; Born TL; Bertolaet BL; Knudsen KE; Arden KC; Henry RR; Feramisco JR
    Cancer Res; 1998 May; 58(9):2042-9. PubMed ID: 9581851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A GRIP-1-EZH2 switch binding to GATA-4 is linked to the genesis of rhabdomyosarcoma through miR-29a.
    Song YL; Yang MH; Zhang S; Wang H; Kai KL; Yao CX; Dai FF; Zhou MJ; Li JB; Wei ZR; Yin Z; Zhu WG; Xue L; Zang MX
    Oncogene; 2022 Dec; 41(49):5223-5237. PubMed ID: 36309571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma.
    Taulli R; Foglizzo V; Morena D; Coda DM; Ala U; Bersani F; Maestro N; Ponzetto C
    Oncogene; 2014 May; 33(18):2354-62. PubMed ID: 23728344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ppp1r1b-lncRNA inhibits PRC2 at myogenic regulatory genes to promote cardiac and skeletal muscle development in mouse and human.
    Kang X; Zhao Y; Van Arsdell G; Nelson SF; Touma M
    RNA; 2020 Apr; 26(4):481-491. PubMed ID: 31953255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells.
    Zhang M; Zhu B; Davie J
    J Biol Chem; 2015 Jan; 290(1):310-24. PubMed ID: 25404735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of Thr115 in MyoD positively regulates function in murine fibroblasts and human rhabdomyosarcoma cells.
    Liu LN; Dias P; Houghton PJ
    Cell Growth Differ; 1998 Sep; 9(9):699-711. PubMed ID: 9751114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.
    Skrzypek K; Kusienicka A; Trzyna E; Szewczyk B; Ulman A; Konieczny P; Adamus T; Badyra B; Kortylewski M; Majka M
    Cell Death Dis; 2018 May; 9(6):643. PubMed ID: 29844345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JARID2 and the PRC2 complex regulate skeletal muscle differentiation through regulation of canonical Wnt signaling.
    Adhikari A; Davie J
    Epigenetics Chromatin; 2018 Aug; 11(1):46. PubMed ID: 30119689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.
    Zhu B; Zhang M; Byrum SD; Tackett AJ; Davie JK
    Int J Cancer; 2014 Aug; 135(4):785-97. PubMed ID: 24470334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.
    Marchesi I; Sanna L; Fais M; Fiorentino FP; Giordano A; Bagella L
    J Cell Physiol; 2018 Mar; 233(3):2360-2365. PubMed ID: 28722764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
    Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.